Abstracts Archive - Page 2404 of 2425 - ACR Meeting Abstracts

Abstract Number: 251 • 2012 ACR/ARHP Annual Meeting
Smaller Baseline and Follow-up Quadriceps Muscle Cross-Sectional Area Increases the Odds of Knee Replacement in Knee Osteoarthritis
Serter Gumus¹, Michael J. Hannon², Diana Kaya¹, C. Kent Kwoh³ and Kyongtae Ty Bae¹, ¹Radiology, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee osteoarthritis (OA) is one of the major causes of disability among elderly. Knee replacement (KR) is the final effective treatment of OA after…
Abstract Number: 252 • 2012 ACR/ARHP Annual Meeting
Presence of Severe Medial Mensical Pathology Increases the Odds for Knee Replacement: Data From the Osteoarthritis Initiative
Frank Roemer¹, C. Kent Kwoh², David J. Hunter³, Robert M. Boudreau⁴, Michael J. Hannon⁵, Markus R. John⁶, Felix Eckstein⁷, Michel Crema⁸, Zhijie Wang⁵ and Ali Guermazi⁸, ¹Klinikum Augsburg, Augsburg, Germany, ²School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁴Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ⁸Boston University, Boston, MA
Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcome. However, at present there is no clear consensus on indications for KR.…
Abstract Number: 253 • 2012 ACR/ARHP Annual Meeting
Incidence of Osteoarthritis-Related Knee and Hip Joint Surgery in Southern Sweden
Aleksandra Turkiewicz¹, Ingemar F. Petersson², Leif E. Dahlberg¹ and Martin Englund¹, ¹Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: To estimate the incidence and age and sex patterns of subjects having had osteoarthritis (OA)-related surgical treatment. Methods: The Skåne Health Care Register (SHCR)…
Abstract Number: 254 • 2012 ACR/ARHP Annual Meeting
Effects of Strontium Ranelate On Knee Osteoarthritis Pain: A Responder Analysis
JY. Reginster¹, Roland Chapurlat², N. Bellamy³, E. Czerwinski⁴, JP Devogelaer⁵, Lyn March⁶, K. Pavelka⁷ and Cyrus Cooper⁸, ¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Hôpital Edouard Herriot, Lyon, France, ³CONROD. The University of Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, ⁴Krakow Medical Centre, Kraków, Poland, ⁵Service de Rhumatologie, Cliniques Universitaires St. Luc, Brussels, Belgium, ⁶University of Sydney, Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards - Sydney, Australia, ⁷Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁸NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom
Background/Purpose: In a large, randomised, placebo-controlled, double-blind phase-III 3-year study (SEKOIA), strontium ranelate 2g/day (SrRan) has demonstrated structure-modifying activity associated with statistically significant symptomatic improvement…
Abstract Number: 255 • 2012 ACR/ARHP Annual Meeting
Clinically Meaningful Effect of Strontium Ranelate On Knee Osteoarthritis Symptoms
O. Bruyere¹, N. Bellamy², J. Brown³, P. Richette⁴, L. Punzi⁵, X. Chevalier⁶, Cyrus Cooper⁷ and Jean-Yves Reginster¹, ¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²CONROD. The University of Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, ³Rheumatology Centre,, Quebec City, QC, Canada, ⁴Centre Viggo Petersen / Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ⁵Cattedra e Divisione di Reumatologia, Azienda Ospedaliera di Padova, Padova, Italy, ⁶Service de Rhumatologie, Hôpital Henri-Mondor, Creteil, France, ⁷NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom
Background/Purpose: In the SEKOIA study, strontium ranelate 2g/day has been demonstrated to reduce total WOMAC score, pain subscore and global knee pain assessed using a…
Abstract Number: 256 • 2012 ACR/ARHP Annual Meeting
Strontium Ranelate Decreases the Level of Urinary CTX-II in Patients with Knee Osteoarthritis
Julien Collette¹, Olivier Bruyere² and Jean-Yves Reginster³, ¹University of Liege, Labo Ria Chu Sart Tilman, Liege, Belgium, ²Public Health/Epidemiology, University of Liege, Liege, Belgium, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
Background/Purpose: Knee osteoarthritis is a chronic disease affecting the global joint and characterized by cartilage degradation as well as subchondral bone remodelling. Effects of strontium…
Abstract Number: 257 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee
Matthias Rother¹, Johannes C. Vester², Wolfgang W. Bolten³ and Philip G. Conaghan⁴, ¹IMR Partner GmbH, Graefelfing, Germany, ²IDV Data Analysis and Study Planning, Krailling, Germany, ³Rheumatology, Klaus-Miehlke-Klink, Wiesbaden, Germany, ⁴University of Leeds, Leeds, United Kingdom
Background/Purpose: A transfersome is an ultradeformable lipid vesicle originally developed to deliver high concentrations of drug (eg NSAIDs) transdermally. Large interventional trials in osteoarthritis (OA)…
Abstract Number: 258 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of the Chinese Herbal Compound Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of the Knee: Results of a Phase II International Study
Marc C. Hochberg¹, Lixing Lao², Patricia Langenberg³, Harry H. S. Fong⁴, David Y-W. Lee⁵ and Brian Berman², ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Center for Integrative Medicine, University of Maryland, Baltimore, MD, ³University of Maryland, Baltimore, MD, ⁴University of Illinois at Chicago, Chicago, IL, ⁵Harvard Medical School, Boston, MA
Background/Purpose: Traditional Chinese Medicine (TCM), which includes the use of herbal medicines, is widely used to treat osteoarthritis (OA) of the knee in Asian societies;…
Abstract Number: 259 • 2012 ACR/ARHP Annual Meeting
Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Alfonso E. Bello¹, Evan F. Ekman², David Radin³, Isabelle Davignon⁴, Michael D. Smith⁵, Mark T. Brown⁵, Christine R. West⁶ and Kenneth M. Verburg⁵, ¹Illinois Bone & Joint Institute, Glenview, IL, ²Southern Orthopaedic Sports Medicine, Columbia, SC, ³Stamford Therapeutics Consortium, Stamford, CT, ⁴Pfizer, Groton, CT, ⁵Pfizer, Inc., Groton, CT, ⁶Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Nerve growth factor (NGF) levels are associated with increased pain perception and are elevated in joints of arthritis patients. Tanezumab, a humanized monoclonal antibody,…
Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…
Abstract Number: 261 • 2012 ACR/ARHP Annual Meeting
Effect of Advancing Age On the Gastrointestinal Safety of Celecoxib Versus Nonselective Nonsteroidal Anti-Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons
Lee S. Simon¹, Byron Cryer², Gurkirpal Singh³, Chunming Li⁴ and Margaret Noyes Essex⁵, ¹SDG LLC Consulting, West Newton, MA, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer, Inc, New York, NY
Background/Purpose: Celecoxib use was associated with a lower risk of clinically relevant upper and lower GI events than nonselective (ns)NSAIDs in patients (≥ 55 years)…
Abstract Number: 262 • 2012 ACR/ARHP Annual Meeting
Flexible Footwear Reduces Dynamic Joint Loads in Knee Osteoarthritis: Results of a 6 Month Randomized Controlled Trial
Najia Shakoor¹, Roy H. Lidtke², Louis F. Fogg³, Rachel A. Mikolaitis², Markus A. Wimmer⁴, Kharma C. Foucher⁴, Laura E. Thorp⁵ and Joel A. Block², ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Nursing, Rush University Medical Center, ⁴Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ⁵Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL
Background/Purpose: Dynamic joint loads are important in the pathophysiology of knee OA and biomechanical interventions aim to reduce these loads in hopes of improving symptoms…
Abstract Number: 263 • 2012 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-Analysis
Fabiola Atzeni¹, Pier Carlo Sarzi-Puttini¹, Luigi Lanata² and Michela Bagnasco², ¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ²Medical Department, Dompé SpA, Milan, Italy
Background/Purpose : The management of mild-to-moderate pain has traditionally been based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the synthetic non-opioid analgesic paracetamol…
Abstract Number: 264 • 2012 ACR/ARHP Annual Meeting
Specialized Footwear Decreases Medial Tibial Bone Mineral Density Over 48 Weeks in Knee Osteoarthritis
Justin B. Gan¹, Laura E. Thorp², Roy H. Lidtke³, Rachel A. Mikolaitis³, Louis F. Fogg⁴, Joel A. Block³ and Najia Shakoor¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Department of Nursing, Rush University Medical Center, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is characterized by increased subchondral bone mineral density at affected joints. In the knee, proximal tibial bone mineral density (BMD) is…
Abstract Number: 265 • 2012 ACR/ARHP Annual Meeting
Reducing Loads in the Contralateral Side in Medial Knee Osteoarthritis; A 3-Year Follow-up Study
Roy H. Lidtke and Joel A. Block, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: No strategies have been shown to prevent Medial knee osteoarthritis (MKOA). For those with symptomatic unilateral MKOA, the contralateral knee may be at risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].